# Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

> **NCT00968851** · PHASE2 · COMPLETED · sponsor: **FORUM Pharmaceuticals Inc** · enrollment: 317 (actual)

## Conditions studied

- Schizophrenia
- Central Nervous System Diseases
- Cognition

## Interventions

- **DRUG:** EVP-6124
- **DRUG:** Placebo
- **DRUG:** EVP-6124

## Key facts

- **NCT ID:** NCT00968851
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-03
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2014-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00968851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00968851, "Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00968851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*